share_log

藥明康德：翌日披露報表

WUXI APPTEC: Next Day Disclosure Return

Hong Kong Stock Exchange ·  Apr 15 04:30
Summary by Moomoo AI
無錫藥明康德新藥開發股份有限公司於2024年3月11日至4月15日期間，進行了多次股份回購活動。根據公司提交的翌日披露報表，公司在上述期間內共回購了數百萬股A股股份，每次回購的股份數目及發生變動的日期均有詳細記錄。回購價格與市場價格相比，呈現出不同程度的折讓或溢價。最後一次回購發生在2024年4月15日，當日公司回購了473,700股A股股份，總金額達到人民幣20,049,239元。該系列股份回購行動是根據相關規則在上海證券交易所進行的，並且公司確認所有交易均符合當地規定。
無錫藥明康德新藥開發股份有限公司於2024年3月11日至4月15日期間，進行了多次股份回購活動。根據公司提交的翌日披露報表，公司在上述期間內共回購了數百萬股A股股份，每次回購的股份數目及發生變動的日期均有詳細記錄。回購價格與市場價格相比，呈現出不同程度的折讓或溢價。最後一次回購發生在2024年4月15日，當日公司回購了473,700股A股股份，總金額達到人民幣20,049,239元。該系列股份回購行動是根據相關規則在上海證券交易所進行的，並且公司確認所有交易均符合當地規定。
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted several share repurchases from March 11 to April 15, 2024. According to the Company's Next Day Disclosure Report, the Company repurchased a total of millions of shares of A-shares during the above period, with detailed records of the number of shares repurchased and the date of the change. The repurchase price presents a different degree of discount or premium compared to the market price. The last repurchase took place on April 15, 2024, on which day the company repurchased 473,700 shares of A-shares for a total amount of RMB20,049,239. The repurchase of the series of shares is carried out in accordance with the relevant rules at the Shanghai Stock Exchange, and the company confirms that all transactions comply with local regulations.
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted several share repurchases from March 11 to April 15, 2024. According to the Company's Next Day Disclosure Report, the Company repurchased a total of millions of shares of A-shares during the above period, with detailed records of the number of shares repurchased and the date of the change. The repurchase price presents a different degree of discount or premium compared to the market price. The last repurchase took place on April 15, 2024, on which day the company repurchased 473,700 shares of A-shares for a total amount of RMB20,049,239. The repurchase of the series of shares is carried out in accordance with the relevant rules at the Shanghai Stock Exchange, and the company confirms that all transactions comply with local regulations.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more